Abstract
KINASE INHIBITOR, XL820, ADMINISTERED ORALLY TO PATIENTS WITH SOLID TUMORS Kyriakos P. Papadopoulos, Jordi Rodon, Alain Mita, Patricia O’Rourke, Amita Patnaik, Eric Rubin, Anthony W. Tolcher, Mark Stein 2 Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA; Cancer Institute of New Jersey, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
